Rob Genuario

About Rob Genuario

Experienced genomics and precision oncology leader with a large KOL network across academic medical centers, NCI-designated cancer centers, and community oncology groups. Recognized as a trusted advisor in genomics, partnering with oncologists, pathologists, and translational researchers to accelerate adoption of molecular profiling and inform data-driven clinical decisions.Strong understanding of the value of clinicogenomics and real-world evidence (RWE) in addressing unmet needs in oncology—particularly in solid tumors, rare cancers, and population-specific genomic insights. Skilled at bridging scientific, operational, and commercial priorities to deliver solutions that improve patient stratification, clinical trial matching, and biomarker discovery.Specialties:Precision Oncology • Real-World Evidence (RWE) • Clinicogenomics • Solid Tumor Profiling • Next-Generation Sequencing (NGS) • Whole-Genome & Whole-Exome Sequencing • High-Density Genotyping • Epigenomics • Gene Expression • Single-Cell Analysis • miRNA Profiling • Biomarker Development • Molecular Pathology • Oncology Partnerships & KOL Engagement

Experience

1. Vice President Poa Collaborations

   Caris Life Sciences

   Jul 2021 — Present · US

   Lead strategic growth and partnership development for the Precision Oncology Alliance (POA), a global network of NCI-designated cancer centers, academic medical centers, and leading community oncology groups.Responsible for expanding and strengthening high-value institutional relationships, driving adoption of Caris’ molecular profiling, clinicogenomic datasets, and real-world evidence capabilities. Serve as a trusted genomics advisor to executive leadership, KOL oncologists, and translational researchers across top-tier institutions.Key contributions include:• Growing and managing relationships with institutions of strategic significance across the POA network• Advising on the integration of clinicogenomics into research programs, clinical trial strategies, and precision oncology initiatives• Supporting enterprise-level collaborations that leverage multi-modal data (NGS, clinical, molecular, real-world evidence)• Connecting oncologists, physician-scientists, and investigators to Caris’ data insights, profiling technology, and research infrastructure• Driving cross-functional alignment between medical affairs, scientific operations, commercial teams, and research partners

Education

• University of Medicine and Dentistry of New Jersey -New Jersey Medical School

  PhD

• Fox Chase Cancer Center

  Post Doc

Skills

• Commercialization
• Gene Expression
• Immunohistochemistry
• Qpcr
• Oncology
• Drug Discovery
• Molecular Biology
• Cell Biology
• Microarrays
• Cancer
• Biopharmaceuticals
• Laboratory Automation
• Mirna
• Genotyping
• Genetics
• Proteomics
• Pcr
• Biochemistry
• Infectious Diseases
• Elisa
• Lifesciences
• Purification
• Dna Sequencing
• Medical Diagnostics
• Genomics
• Molecular Diagnostics
• Microarray
• Flow Cytometry
• Assay Development
• Bioinformatics
• Sequencing
• Protein Chemistry
• Hardware Diagnostics
• Personalized Medicine
• Immunoassays
• Cell
• Dna
• Technology Transfer
• Life Sciences
• Biotechnology